Post by chrocary / Jane on May 23, 2015 14:33:02 GMT -5
Marijuana seems to have such a bad rep until the medical benefits of it are now coming to light.
When you see and hear about the benefits from Cancer patients and now quite a few other diseases it makes you wonder. In the past I may recall the relaxation benefit and sleeping benefit of it and although you obviously shouldn't be smoking it........there was a discussion of brownies and cookies. Count_Sheep
Just might be worth looking into, although I know my doctor would never condone it and of coarse Canada will likely be the last to legalize it.........still.........
My lungs are so far gone that I have trouble with second hand tobacco smoke, diesel exhaust, and forest fire smoke. I couldn't imagine the irritation that cannabis smoke might cause. As for "vaporizers", toasting rather than burning still generates lots of particulates. Wouldn't put my face over a toaster that was blackening bread, even if there were no flames.
I'd want to see some pretty strong research from major medical sources before I'd buy into any claims that cannabis might help my emphysema. If it did turn out to help, perhaps a nebulized delivery would be the safest for people with lung problems.
By the time that is available, I expect to be long past caring whether I'm breathing at all.
Here is a rather long video of Treating Emphysema / COPD with Medical Cannabis
Published on Jul 15, 2012
Medical marijuana patient and double lung transplant candidate Vey Linville discusses using marijuana to treat his severe emphysema and tells the truth about dispensaries in San Diego, the recent federal crackdown in California, and his efforts in Imperial Beach.
Looks like there is a support study starting up: -----------------------------
InMed Launches Study on Cannabis-Based COPD Therapy
InMed Pharmaceuticals is expanding its product line by initiating studies on a potential treatment for chronic obstructive pulmonary disease (COPD). The clinical stage company specializes in the development of therapeutic options based on cannabis, and will launch a new program designed to discover and assess cannabinoid compounds able to treat COPD.
InMed announced that its new program focused on finding cannabis-based treatments for COPD has already initiated its first drug discovery efforts and preclinical tests in partnership with investigators from the Department of Anesthesiology, Pharmacology & Therapeutics at the University of British Columbia in Vancouver, Canada.
“We’re excited to explore avenues to further expand InMed’s pipeline with the addition of new program targeting COPD, the third leading cause of death in the United States,” said InMed’s president and CEO Craig Schneider. COPD is a chronic pulmonary disease that affects more than 50 million people worldwide and progressively degrades the ability to breathe, increasing mucus production, cough and chest tightness.
“Similar to our ongoing program in orofacial pain, we are leveraging our proprietary intelligent drug design platform technology to identify promising therapeutic candidates. In addition to advancing our current product candidates, expansion into respiratory disease marks our fourth major disease focus, highlighting our commitment to building a leading pipeline of cannabinoid-based therapies,” added Schneider.
Previous research has suggested the effectiveness of cannabinoid compounds in improving COPD symptoms, since the most significant active ingredient in cannabis, THC, has the ability to provoke short-term bronchodilation. In addition, cannabinoids may also disable the proliferation and activation of T-cells and have anti-inflammatory proprieties.
“Current treatments for COPD are complex and ineffective and there is currently no cure available. It is well known that cannabinoids exhibit bronchodilatory, immunosuppressive, and anti-inflammatory properties and thus cannabinoid-based therapy may offer safer and more effective treatment options for COPD,” explained the chief scientific officer at the company, Sazzad Hossain.
The initial research is being conducted by InMed investigator Dmitri Pechkovsky, who is working in collaboration with Pascal Bernatchez in his lab at the University of British Columbia. With a PhD in Immunology and Allergy from Minsk State Medical Institute in Belarus and post-doctoral training from the Research Center Borstel-Leibniz Center for Medicine and Biosciences (FZB), Luebeck University, and University of Freiburg in Germany, Pechkovsky has proven experience in studying pulmonary diseases, such as COPD, idiopathic pulmonary fibrosis and asthma.